Start here if you're new
what it is
Ginkgo runs lab services that help companies program cells and detect biological threats.
how it gets paid
Last year Ginkgo Bioworks made $170M in revenue.
why growth slowed
Revenue fell 25.1% last year. Latest-quarter revenue jumped 252% vs. prior year, but earnings stayed deeply negative.
what just happened
Revenue hit $137M last quarter, but EPS was still -$4.22.
At a glance
C+ balance sheet — struggling to keep the lights on
-$10.54 fy2024 eps est
$227M fy2024 rev est
n/a operating margin
2.1 beta
xvary composite: 29/100 — weak
What they do
Ginkgo runs lab services that help companies program cells and detect biological threats.
The moat is workflow, not a box. Ginkgo says it builds end-to-end services and does not make products, so your program sits inside its lab stack instead of a shelf item. That matters because $170M of trailing revenue comes from services across food, agriculture, pharma, and specialty chemicals, and moving a biology project means rebuilding the setup elsewhere.
How they make money
$170M
annual revenue · revenue declined -25.1% last year
total revenue
$170M
25.1%
The products that matter
custom organism design
Foundry Services
$131M · 77% of shown revenue
this is the main business at $131M, and it still fell 25.1% from a year ago. if this line does not stabilize, the rest of the story becomes academic.
core revenue line
pathogen monitoring services
Biosecurity
$39M · 23% of shown revenue
biosecurity brought in $39M and also fell 25.1%. that means the backup engine is shrinking at the same speed as the main one.
shrinking support line
remote lab automation
Ginkgo Cloud Lab
launched mar 2026
management launched this in March 2026 as the new commercial angle. the number that matters next is simple: any disclosed revenue, because right now the market is underwriting promise.
the new bet
Key numbers
$170M
annual revenue
That is a small top line next to a $401M market cap. You are paying about 2.4x sales for a company still losing money.
-185.3%
operating margin
For every $1 of sales, the business lost about $1.85 at the operating level. That is a cash burn problem, not a branding problem.
$423M
long-term debt
Debt is larger than revenue by $253M. That leaves less room for mistakes.
2.1
beta
A beta of 2.1 means the stock moves about twice as hard as the market. You are buying volatility with a company attached to it.
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $423M (51% of capital)
C+ — balance sheet grade and long-term debt are flagged. this stock carries more risk than average.
Total return vs. market
Return history isn't available for DNA right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Revenue hit $137M last quarter, but EPS was still -$4.22.
Latest-quarter revenue jumped 252% vs. prior year, but earnings stayed deeply negative. The business is scaling off a low base, not printing profit.
$137M
revenue
-$4.22
eps
n/a
n/a
the number that mattered
The $137M revenue print matters because it shows the top line can move fast. The loss still means scale has not fixed the business.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is turning Ginkgo Cloud Lab into real revenue before the current loss profile overwhelms the balance sheet.
med
losses still exceed revenue
Trailing revenue is $170.16M. Net loss is $312.76M. That is not a margin problem around the edges. It is the business model in its current form.
If that ratio does not improve fast, outside capital matters more than customer demand.
med
both reported segments are shrinking
Foundry Services fell 25.1% and Biosecurity fell 25.1% from a year ago. When both engines are moving backward, there is no stabilizer inside the model.
That exposes essentially all of the $170M revenue base to continued contraction.
med
the pivot is early and unproven
Cloud Lab launched in March 2026, which means investors are being asked to believe before they can measure. New products fix old economics only when customers actually show up.
Until management discloses meaningful adoption, the platform thesis is still mostly narrative.
med
capital structure and volatility
Long-term debt stands at $423M, or 51% of capital, while beta is 2.1 and price stability is 5 out of 100. This is not a stock that gives management much room to miss quietly.
When financing risk meets a small-cap chart, dilution and drawdowns stop being abstract.
$423M of long-term debt against $170.16M in trailing revenue and a -183.8% net margin means the company does not need a better story first. it needs better economics.
source: institutional data · regulatory filings · risk analysis
Pay attention to
the number that mattered
losses need to fall below revenue
Right now net loss is $312.76M against $170.16M in revenue. Until that flips into something less absurd, every new strategy deserves skepticism.
calendar
Q1 2026 earnings report
Next report expected May 12, 2026. You want evidence that revenue is stabilizing, not another quarter where the future story gets longer and the current numbers get smaller.
trend
Cloud Lab adoption
The March 2026 launch is the new thesis in public. Watch for any disclosed bookings, revenue contribution, or repeat-customer commentary.
risk
segment declines
Foundry Services and Biosecurity both fell 25.1%. If that does not improve, the pivot is being layered on top of a shrinking base.
Analyst rankings
coverage depth
thin
few clean ranking signals show up in the current feed. in human-speak, you are mostly underwriting management's pivot rather than a strong analyst consensus.
earnings outlook
still negative
The fy2024 EPS estimate sits at -$10.54. Translation: the street does not expect profitability to show up soon.
target visibility
limited
Price target data is not available here. That matters less than it sounds, because for a stock like this the operating trajectory matters more than a spreadsheet midpoint.
source: institutional data
Institutional activity
institutional ownership data for DNA is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$10
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive